See more : Chindata Group Holdings Limited (CD) Income Statement Analysis – Financial Results
Complete financial analysis of PetIQ, Inc. (PETQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PetIQ, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Catalent, Inc. (CTLT) Income Statement Analysis – Financial Results
- By-health Co., Ltd. (300146.SZ) Income Statement Analysis – Financial Results
- Thunder Software Technology Co.,Ltd. (300496.SZ) Income Statement Analysis – Financial Results
- LWS Knitwear Limited (LWSKNIT.BO) Income Statement Analysis – Financial Results
- Nova Minerals Limited (NVAWW) Income Statement Analysis – Financial Results
PetIQ, Inc. (PETQ)
About PetIQ, Inc.
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at 2,900 community clinics and wellness centers hosted at pet retailers across 42 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.10B | 921.51M | 932.53M | 780.05M | 709.43M | 528.61M | 266.69M | 200.16M | 205.69M | 161.49M |
| Cost of Revenue | 849.22M | 711.85M | 746.14M | 644.86M | 602.05M | 445.33M | 215.49M | 167.62M | 166.53M | 139.69M |
| Gross Profit | 252.74M | 209.66M | 186.39M | 135.19M | 107.38M | 83.29M | 51.19M | 32.55M | 39.16M | 21.80M |
| Gross Profit Ratio | 22.94% | 22.75% | 19.99% | 17.33% | 15.14% | 15.76% | 19.20% | 16.26% | 19.04% | 13.50% |
| Research & Development | 1.10M | 2.10M | 8.00M | 2.30M | 1.30M | 203.00K | 514.00K | 310.00K | 380.00K | 1.14M |
| General & Administrative | 146.03M | 162.46M | 170.52M | 138.38M | 103.20M | 72.26M | 37.91M | 31.85M | 35.59M | 23.42M |
| Selling & Marketing | 45.60M | 20.10M | 16.20M | 10.10M | 4.50M | 2.90M | 2.20M | 1.20M | 6.08M | 5.49M |
| SG&A | 191.63M | 182.56M | 170.52M | 138.38M | 103.20M | 72.26M | 37.91M | 31.85M | 35.59M | 28.91M |
| Other Expenses | -160.00K | 130.00K | 1.92M | 571.00K | 172.00K | -345.00K | 201.00K | 666.00K | 0.00 | 0.00 |
| Operating Expenses | 192.73M | 182.56M | 170.52M | 138.38M | 103.20M | 72.26M | 37.91M | 31.85M | 35.59M | 31.81M |
| Cost & Expenses | 1.04B | 894.41M | 916.66M | 783.24M | 705.25M | 517.59M | 253.40M | 199.46M | 202.12M | 171.50M |
| Interest Income | 0.00 | 27.40M | 24.70M | 22.81M | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 980.00K |
| Interest Expense | 34.55M | 27.37M | 24.70M | 26.30M | 14.50M | 8.02M | 1.56M | 3.06M | 3.55M | 0.00 |
| Depreciation & Amortization | 44.57M | 32.62M | 36.67M | 24.88M | 15.14M | 11.90M | 3.40M | 2.98M | 3.14M | 2.30M |
| EBITDA | 81.49M | 12.59M | 48.85M | 22.38M | 12.42M | 19.62M | 16.83M | 2.65M | 4.77M | -5.96M |
| EBITDA Ratio | 9.49% | 6.80% | 6.12% | 3.64% | 2.94% | 4.38% | 6.41% | 2.72% | 3.26% | -3.69% |
| Operating Income | 60.02M | 27.23M | 15.87M | -2.62M | 4.36M | 7.75M | 13.29M | 702.00K | 3.57M | -8.25M |
| Operating Income Ratio | 5.45% | 2.96% | 1.70% | -0.34% | 0.61% | 1.47% | 4.98% | 0.35% | 1.74% | -5.11% |
| Total Other Income/Expenses | -34.71M | -27.24M | -28.39M | -22.13M | -14.47M | -8.32M | -1.50M | -4.10M | -4.92M | -870.00K |
| Income Before Tax | 2.37M | -47.41M | -12.51M | -28.81M | -17.61M | -574.00K | 11.79M | -3.40M | -1.35M | -10.99M |
| Income Before Tax Ratio | 0.21% | -5.14% | -1.34% | -3.69% | -2.48% | -0.11% | 4.42% | -1.70% | -0.66% | -6.81% |
| Income Tax Expense | -173.00K | 1.21M | 3.87M | 52.22M | -3.31M | -661.00K | 3.97M | 3.00K | -1.35M | -6.00K |
| Net Income | 2.13M | -48.62M | -16.38M | -81.02M | -14.30M | -782.00K | -3.49M | -3.40M | -1.35M | -10.99M |
| Net Income Ratio | 0.19% | -5.28% | -1.76% | -10.39% | -2.02% | -0.15% | -1.31% | -1.70% | -0.66% | -6.80% |
| EPS | 0.07 | -1.67 | -0.58 | -3.29 | -0.63 | -0.05 | -0.26 | -0.28 | -0.11 | -0.89 |
| EPS Diluted | 0.07 | -1.67 | -0.58 | -3.29 | -0.63 | -0.05 | -0.26 | -0.28 | -0.11 | -0.89 |
| Weighted Avg Shares Out | 29.14M | 29.16M | 28.24M | 24.63M | 22.65M | 17.22M | 13.22M | 12.29M | 12.29M | 12.29M |
| Weighted Avg Shares Out (Dil) | 29.53M | 29.16M | 28.24M | 24.63M | 22.65M | 17.22M | 13.22M | 12.29M | 12.29M | 12.29M |
Fast-paced Momentum Stock PetIQ (PETQ) Is Still Trading at a Bargain
PetIQ, Inc.'s New SENTRY® Portable Calming Diffuser Helps Calm Dogs and Cats During the Busy Holiday Season and Beyond
Higher prices are squeezing pet owners. Analysts say this online retailer ‘appears insulated.
Should Value Investors Buy PetIQ (PETQ) Stock?
PETQ vs. ABT: Which Stock Is the Better Value Option?
PetIQ (PETQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Are Investors Undervaluing PetIQ (PETQ) Right Now?
PETQ vs. ABT: Which Stock Should Value Investors Buy Now?
Should Value Investors Buy PetIQ (PETQ) Stock?
Is It Time to Buy This Year's Worst-Performing Growth Stocks?
Source: https://incomestatements.info
Category: Stock Reports